Metformin changes the expression pattern of immune mediators in hepatocellular carcinoma (HCC) immune microenvironment, including PD-1, cytotoxic T lymphocyte antigen-4 (CTLA-4) [88]. Here, CTLA4 is linked to hepatocellular carcinoma.